Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $409.0 million Upfront Cash: $32.0 million
Deal Type: Collaboration June 25, 2020
Sosei Heptares will apply its proprietary StaR® technology and GPCR-focused Structure-based Drug Design (SBDD) capabilities and fund R&D activities through the completion of Investigational New Drug (IND)-enabling studies.